Press
releases

Dompé Announces Activation of U.S. Clinical Trial Sites for Phase 3 Study of Reparixin, an Oral Investigational CXCR1/CXCR2 Inhibitor, in Hospitalized Patients with Severe COVID-19 Pneumonia

June 3, 2021

EXSCALATE4COV: Italian Medicines Agency (AIFA) authorizes Raloxifene Clinical Trial for Paucisymptomatic Covid-19 Patients treated at Home and in Medical Facilities

October 27, 2020

Dompé Appoints New Global Biotech Head

September 21, 2020

EU-supported Private-Public Consortium Exscalate4CoV : Raloxifene proposed for clinical trials after tests show it inhibits SARS-CoV-2

June 18, 2020

Dompé Presents Phase II Clinical Trial Results for Ladarixin in New-Onset Type 1 Diabetes at the American Diabetes Association’s Scientific Sessions

June 15, 2020

Dompé to Present Phase II Clinical Data for Ladarixin in New-Onset Type 1 Diabetes (T1D) at the American Diabetes Association’s Scientific Sessions

June 8, 2020

AIFA Announces Italian Authorization of Phase 2/3 Clinical Trial of Dompé’s Reparixin for the Treatment of Severe Patients with COVID-19 Pneumonia

May 12, 2020

Exscalate4CoV supercomputing platform wins 3 million euro EU funding to hunt for new drugs against Coronavirus pandemic

March 6, 2020

Exscalate4CoV: EU’s supercomputing and life science champions gear-up to fight Coronavirus pandemic

February 17, 2020

The Galien Foundation Debuts 2019 Prix Galien USA Nominees in "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Medical Technology" Categories

July 15, 2019